EMA bans APIs from two Indian manufacturers


Italian regulators recently inspected a couple of Indian API makers and came away with concerns. Now the European Medicines Agency has called for recalls of all of their products and banned them from future shipments.

The actions were taken against a JP Laboratories unit in Maharashtra and a Krebs Biochemicals & Industries plant in Andhra Pradesh following inspections in March. 

In the case of API maker JP Laboratories, inspectors documented 28 deficiencies, 9 of them major. Those involved quality management and data integrity, as well as materials management, equipment validation and others. The problems were so pervasive that regulators said, “The extent and severity of the findings, in combination with the repeated negative inspection outcome, demonstrates the inability of the company to sustain an acceptable GMP compliance level, and constitutes a critical risk for public health.”


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

The EMA pulled the plant’s certificate of suitability and the agency recommended that all of JP Laboratories' products be recalled, unless countries determine it would lead to shortages of specific meds in their areas.

With simvastatin API maker Krebs, inspectors documented 24 deficiencies, 5 of which were considered major. The regulator said weaknesses in quality management at the plant “demonstrated a critical risk to public health.” The major deficiencies were in several areas including deviation management and the plant’s monitoring of purified water.  

The EMA also pulled the certificate of suitability for Krebs and suggested that countries recall its products as well.  

Like the U.S., Europe gets much of its API production from India and so monitors the industry there closely. The EMA has taken actions against half a dozen Indian manufacturers since the first of the year but has also taken steps against plants in China, Spain, France and even in the U.S. Last week, at the suggestion of inspectors from Sweden, the agency banned products from Capsugel’s Bend Research facility in Oregon over what it termed “Repeated failures to correct deficiencies and to provide requested and reliable information.”

- access the reports here 

Related Articles: 
Anuh Pharma plant savaged in EMA report 
Rusan plant in India remains under EU ban due to persistent GMP problems   
EMA pulls GMP certificate for U.S. facility


Suggested Articles

Indoco Remedies is not just getting the once over by the FDA but the twice-over as inspectors work through its plants and citations rain down. 

Drugmakers have speculated about delivering temperature-sensitive vaccines and drugs using drones. Now, Merck & Co. is testing the method. 

Nexus Pharmaceuticals has moved forward the first phase of a 10-year, $250 million project to build out its sterile drug production operations.